Search Clinical Trials in the European Union

Duration
16-20 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
61-80 of 112 trials

Multiple Sclerosis: ABP 692 vs. Ocrevus

We are comparing a new treatment called ABP 692 with Ocrevus for people with relapsing-remitting multiple sclerosis. The goal is to see how they differ in effectiveness and safety.

Relapsing-Remitting Multiple Sclerosis>2 yearsConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementNeurology

Recurrent Lower Respiratory Tract Infections: Buccalin Tablets

We are studying Buccalin tablets to see if they can help prevent recurrent lower respiratory tract infections. This trial aims to gather more information on their safety and effectiveness.

Recurrent Lower Respiratory Tract InfectionsMonitoring phase (IV)16-20 visitsStandard MedicinesInternal MedicinePulmonology

Invasive Aspergillosis: Olorofim vs. AmBisome®

We are studying a new treatment called olorofim for patients with invasive aspergillosis to see if it works better and is safer than the standard treatment, AmBisome®. This trial will also look at how these treatments affect patients' quality of life.

Invasive Fungal Infection3-6 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInfectious DiseasesInternal Medicine

Generalized Anxiety Disorder: MM120 Medication Study

We are testing a new oral medication, MM120, to see if it helps reduce anxiety symptoms in adults with generalized anxiety disorder. The study will also look at its effects on quality of life and sexual functioning.

Generalized Anxiety Disorder1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemotePsychiatry

BRAF Alterations in Cancer: FORE8394 Treatment Study

We are testing the drug FORE8394 in patients with advanced solid tumors or specific brain tumors that have BRAF alterations. The goal is to see if it can effectively treat these cancers.

BRAF Gene MutationEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Pulmonary Arterial Hypertension: LTP001 Treatment Study

We are studying a new treatment called LTP001 in healthy adults and in individuals with pulmonary arterial hypertension. The goal is to evaluate its safety and how well it may improve exercise capacity and overall health.

Pulmonary Arterial HypertensionSafety phase (I)Efficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPulmonology

Kidney Transplant: Eight Treg Immunotherapy

We are testing a new treatment using expanded regulatory T cells for living donor kidney transplant recipients. The goal is to see if this approach is safe and may reduce the need for traditional immunosuppressive medications.

Chronic Kidney FailureSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesInternal MedicineNephrology

Type 1 Diabetes: Low-Dose Interleukin-2 Study

We are studying the effects of low-dose interleukin-2 on patients with type 1 diabetes who still have some insulin production. The aim is to see if this treatment can help improve their immune response and insulin levels.

Type 1 DiabetesEfficacy phase (II)16-20 visitsInvestigational MedicinesEndocrinologyInternal Medicine

Cholangiocarcinoma: Ivosidenib with Durvalumab and Gemcitabine/Cisplatin

We are studying a new treatment combination for patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The goal is to evaluate its safety and early effectiveness as a first-line therapy.

Cholangiocarcinoma>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Ulcerative Pyoderma Gangrenosum: Spesolimab Study

We are testing whether spesolimab can help adults with ulcerative pyoderma gangrenosum heal their skin ulcers better than a placebo. This study aims to evaluate its safety and effectiveness.

Pyoderma GangrenosumConfirmation phase (III)16-20 visitsStandard MedicinesCost ReimbursementDermatology

Spinocerebellar Ataxia and Huntington’s Disease: VO659 Treatment

We are investigating the safety of a new treatment given through the spine for people with spinocerebellar ataxia types 1 and 3, and Huntington’s disease. This study aims to understand how the body processes the medication.

Spinocerebellar Ataxia Types 1, 3 and Huntington's Disease1-2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteNeurology

Chronic Immune Thrombocytopenia: Mezagitamab Injection

We are studying a new injection, mezagitamab, for adults with chronic immune thrombocytopenia to see if it can improve platelet counts and reduce symptoms compared to a placebo.

Primary Immune Thrombocytopenia6-12 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementHematology

Ileal Crohn’s Disease: AZD7798 Study

We are testing the safety and effectiveness of AZD7798 in adults with ileal Crohn’s disease who have an ileostomy. This study aims to see how well the treatment helps with healing and managing symptoms.

Crohn's Disease1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Breast Cancer: Shorter Hormone Therapy Duration

We are studying whether limiting hormone therapy to 2 years is effective for women with hormone-sensitive breast cancer at very low risk of recurrence. This trial aims to assess the safety and quality of life during and after treatment.

Localized Luminal A Breast Cancer in Post-Menopausal Women>2 yearsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesPartially RemoteEndocrinologyOncology

NPM1-Mutated Acute Myeloid Leukemia: Eltanexor Study

We are evaluating a new drug called eltanexor for patients with relapsed or refractory NPM1-mutated acute myeloid leukemia. The study aims to see if it is safe and effective in treating this condition.

Acute Myeloid LeukemiaEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Rheumatoid Arthritis: CAR-T Therapy vs. Rituximab

We are comparing a new CAR-T cell therapy with rituximab for patients with active rheumatoid arthritis that hasn't responded to other treatments. The goal is to see which therapy is safer and more effective.

Rheumatoid Arthritis1-2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesRheumatology

Hodgkin Lymphoma: Chemotherapy Alone Study

We are exploring whether chemotherapy alone is effective for patients with early-stage Hodgkin Lymphoma who have a good prognosis. This study aims to improve treatment options and monitor for potential relapses.

Classical Hodgkin LymphomaEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Oral Arsenic for Low-Risk Myelodysplastic Syndromes

We are studying whether oral arsenic can help patients with low-risk myelodysplastic syndromes who haven't responded to other treatments. The trial aims to assess its safety and effectiveness over 12 weeks.

Low-Risk Myelodysplastic Syndromes>2 yearsSafety phase (I)16-20 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Aggressive Multiple Sclerosis: Stem Cell Transplant Study

We are investigating whether stem cell transplantation can prevent disease activity in people with aggressive multiple sclerosis. The study will also monitor safety and other health changes over time.

Relapsing-Remitting Multiple Sclerosis>2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyNeurology

Polypoidal Choroidal Vasculopathy: Faricimab Injections

We are studying the effects of faricimab injections on vision improvement in Caucasian patients with polypoidal choroidal vasculopathy. The trial will also assess the treatment's safety and durability.

Polypoidal Choroidal Vasculopathy>2 yearsMonitoring phase (IV)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOphthalmology